From the FDA Drug Label
7.1 Drugs Having Clinically Important Interactions with Aripiprazole Table 25: Clinically Important Drug Interactions with Aripiprazole: Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation ... 7. 2 Drugs Having No Clinically Important Interactions with Aripiprazole Based on pharmacokinetic studies, no dosage adjustment of aripiprazole is required when administered concomitantly with famotidine, valproate, lithium, lorazepam. In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan) when co-administered with aripiprazole. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with aripiprazole [see Clinical Pharmacology (12.3)]
The FDA drug label does not mention DORAs (Dopamine Receptor Agonists) as having any interaction with Abilify (Aripiprazole) 1.
- There is no information about the interaction between DORAs and Abilify.
- The label only discusses interactions with other specific drugs or drug classes.
- No conclusion can be drawn about the interaction between DORAs and Abilify based on the provided drug label.
From the Research
There is no direct interaction between DORAs and Abilify reported in the provided studies, but potential interactions may occur due to their pharmacodynamic and pharmacokinetic properties. The studies provided do not specifically address the interaction between DORAs (dual orexin receptor antagonists) and Abilify (aripiprazole) 2, 3, 4, 5, 6. However, considering the mechanism of action of both medication types, there is a potential for interaction. Aripiprazole, the active ingredient in Abilify, is a partial dopamine agonist with high affinity for dopamine D2 and serotonin 5-HT1A receptors, as well as an antagonist at serotonin 5-HT2A receptors 5, 6. DORAs, on the other hand, promote sleep by inhibiting the orexin receptors.
Some key points to consider:
- Aripiprazole's pharmacodynamics and potential for drug interactions are well-documented, but specific interactions with DORAs are not explicitly mentioned in the provided studies 3, 5, 6.
- The potential for increased sedation or drowsiness when taking both medications together is a consideration, given that DORAs promote sleep and Abilify can cause drowsiness as a side effect.
- Monitoring for side effects and adjusting treatment as necessary is crucial when prescribing multiple medications with potential interactions.
Given the lack of direct evidence on the interaction between DORAs and Abilify, it is essential to prioritize caution and monitor patients closely for potential side effects when co-administering these medications. This approach is in line with the principles of minimizing morbidity, mortality, and optimizing quality of life. If you're currently taking or planning to take both medications, inform your healthcare provider so they can assess your specific situation and make appropriate recommendations based on your medical history and other medications.